MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS) by Jernås, Margareta et al.
Chalmers Publication Library
MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS)
This document has been downloaded from Chalmers Publication Library (CPL). It is the author´s
version of a work that was accepted for publication in:
BMC Immunology (ISSN: 1471-2172)
Citation for the published paper:
Jernås, M. ; Malmeström, C. ; Axelsson, M. (2013) "MicroRNA regulate immune pathways
in T-cells in multiple sclerosis (MS)". BMC Immunology, vol. 14(32),
http://dx.doi.org/10.1186/1471-2172-14-32
Downloaded from: http://publications.lib.chalmers.se/publication/181798
Notice: Changes introduced as a result of publishing processes such as copy-editing and
formatting may not be reflected in this document. For a definitive version of this work, please refer
to the published source. Please note that access to the published version might require a
subscription.
Chalmers Publication Library (CPL) offers the possibility of retrieving research publications produced at Chalmers
University of Technology. It covers all types of publications: articles, dissertations, licentiate theses, masters theses,
conference papers, reports etc. Since 2006 it is the official tool for Chalmers official publication statistics. To ensure that
Chalmers research results are disseminated as widely as possible, an Open Access Policy has been adopted.
The CPL service is administrated and maintained by Chalmers Library.
(article starts on next page)
Jernås et al. BMC Immunology 2013, 14:32
http://www.biomedcentral.com/1471-2172/14/32RESEARCH ARTICLE Open AccessMicroRNA regulate immune pathways in T-cells in
multiple sclerosis (MS)
Margareta Jernås1*, Clas Malmeström2, Markus Axelsson2, Intawat Nookaew5, Hans Wadenvik3, Jan Lycke2
and Bob Olsson4Abstract
Background: MicroRNA are small noncoding RNA molecules that are involved in the control of gene expression.
To investigate the role of microRNA in multiple sclerosis (MS), we performed genome-wide expression analyses of
mRNA and microRNA in T-cells from MS patients and controls.
Methods: Heparin-anticoagulated peripheral blood was collected from MS-patients and healthy controls followed
by isolation of T-cells. MicroRNA and RNA from T-cells was prepared and hybridized to Affymetrix miR 2.0 array and
Affymetrix U133Plus 2.0 Human Genome array (Santa Clara, CA), respectively. Verifications were performed with
real-time polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA).
Results: We identified 2,452 differentially expressed genes and 21 differentially expressed microRNA between MS
patients and controls. By Kolmogorov-Smirnov test, 20 of 21 differentially expressed microRNA were shown to affect
the expression of their target genes, many of which were involved in the immune system. Tumor necrosis factor
ligand superfamily member 14 (TNFSF14) was a microRNA target gene significantly decreased in MS. The differential
expression of mir-494, mir-197 and the predicted microRNA target gene TNFSF14 was verified by real-time PCR
and ELISA.
Conclusion: These findings indicate that microRNA may be important regulatory molecules in T-cells in MS.
Keywords: Autoimmunity, T-cell, Microarray, MicroRNABackground
Multiple sclerosis (MS) is a chronic inflammatory auto-
immune disease characterized by demyelination, astrogli-
osis and damage to oligodendrocytes and axons in the
CNS. The underlying cause and etiology of MS is incom-
pletely understood, but some evidence points to a mul-
tifactorial origin involving both central and peripheral
immunological tolerance mechanisms. An inappropriate
T-cell response to myelin antigens is probably a funda-
mental mechanism in the MS pathophysiology [1,2].
MicroRNA are 19–25 base pair long single stranded
RNA nucleotides. They are evolutionary conserved and
are increasingly regarded as being involved in all aspects
of cellular function in a wide range of eukaryotic organ-
isms [3]. Approximately 33% of the human genes are* Correspondence: margareta.jernas@medic.gu.se
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reproduction in any medium, provided the orestimated to be regulated by microRNA and a single
microRNA can potentially regulate multiple mRNA tar-
gets (in average 200) [4,5]. There are more than 1500
human microRNA identified (http://www.mirbase.org) [6]
and they are associated with major pathologies such as
autoimmune diseases [7-9] and cancer [10]. However, the
in vivo function of most microRNA is largely unknown.
MicroRNA are highly expressed in cells of the immune
system [11,12] and they are involved in numerous path-
ways of both the innate and the adaptive immune system
[3,13-16]. It has been reported that microRNA are crit-
ical for the maintenance of immunological tolerance;
deletion of the enzymes Dicer- and Drosha that are in-
volved in the generation of microRNAs, results in T-cell
abnormalities and autoimmune diseases [17,18]. The
microRNA transcriptome of immune cell subsets are
distinct, suggesting that naïve, effector and central mem-
ory T cell [19] and regulatory T cell function [17,18,20]
are dependent on microRNA regulation. Furthermore,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tors in the differentiation of T cells [21] and associated
with activation of T cell-mediated immune responses
[22]. Several publications have addressed the role of
individual microRNAs in MS [23-34]. However, very
few have performed large scale unbiased studies. Fur-
thermore, most studies have investigated microRNA
expression in peripheral blood mononuclear cells (PBMC).
PBMC is a compartment with heterogeneous cell com-
position due to individual biological variation or disease
state. Therefore, the aim of this study was to identify
differentially expressed microRNA and target mRNA in
T-cells from MS-patients using global DNA microarray
analyses.Methods
Participants
All individuals involved in this study gave informed
consent. The study was approved by the regional ethics
committee in Gothenburg, Sweden.
The ten relapsing remitting MS (RRMS) subjects in
the mRNA analysis (six males and four females; age
38.1 ± 11.7 years) have previously been described [35].
For the microRNA experiment, heparin-anticoagulated
peripheral blood was obtained from 11 (1 male, 10 fe-
males, mean age 42.9 ± 3.4 years) relapsing-remitting
MS (RRMS) patients according to the McDonald cri-
teria [36,37] who were on treatment with beta inter-
feron (Additional file 1: Table S1). The disease duration
was 10.6 ± 2.1 years and neurological deficits were
scored with Expanded Disability Status Scale (EDSS)
[38] and median was 2.1 (range 0–6). Nine healthy indi-
viduals served as controls (4 males, 5 females mean age
42.6 ± 13.6).
For the verification of microRNA experiments by real-
time PCR heparin-anticoagulated peripheral blood was
collected from 16 RRMS patients (1 male, 15 females,
mean age 45.1 ± 2.7) according to the McDonald criteria
[36,37]. The disease duration was 12.0 ± 1.9 years and the
median EDSS score was 2.4 (range 0–6). Twelve healthy
individuals served as controls (6 males, 6 females, mean
age 44.4 ± 12.0). For the verification of mRNA expression
of TNFSF14 by real-time PCR analysis, the same patients
were used, however there were only RNA left from 13 pa-
tients (Additional file 1: Table S1).
For the ELISA experiment, peripheral blood without
anticoagulantia was collected from 16 RRMS patients
(1 male, 15 females, mean age 45.1 ± 2.7) according to
the McDonald criteria [36,37]. The disease duration was
12.0 ± 1.9 years and the median EDSS score was 2.4
(range 0–6) (Additional file 1: Table S1). Twenty healthy
individuals served as controls (6 males, 14 females, mean
age 38.4 ± 12.0).Isolation of T-cells and preparation of RNA
The isolation of T-cells has previously been described [39].
In brief, peripheral blood mononuclear cells (PBMCs)
were separated from heparinized blood immediately
after collection, by density gradient centrifugation using
Ficoll-Paque PLUS (GE Healthcare, Uppsala, Sweden).
After removal of CD14+ cells by magnetic microbeads,
T-cells were positively selected using CD3+ magnetic
microbeads, according to the manufacturer's recom-
mendations (MACS, Miltenyi Biotec, Surrey, UK). The
purity of isolated cells was thereafter determined by
flow cytometry; 93.6-96.2% of the cells were CD3+
T-cells, with no significant differences between the
study groups. The cells were frozen and stored at −80°C.
RNA was isolated from the CD3+ T-cells using the
Chomczynski method [40]. For the microRNA analysis
the RNA was precipitated using isopropanol overnight.
For the DNA microarray analysis the RNA was further
purified using RNeasy MinElute clean-up (Qiagen, Hilden,
Germany). The RNA concentration was measured with
a Nanodrop spectrophotometer and the A260/A280 ra-
tio was 1.8–2.0. The quality of the RNA was verified by
agarose gel electrophoresis for the DNA microarray
analysis. The mean quantity of total RNA from T-cells
in peripheral blood was 5.8 μg (range 1.2-10.3 μg) for
the microRNA analysis and for the DNA microarray
analysis 36.8 μg (1.08-104.88 μg).
Labeling and hybridization to microRNA 2.0 microarrays
1000 ng RNA from T-cells were biotin labeled using the
FlashTag Biotin HSR kit (Genisphere, Hatfield, PA)
according to the manufacturer's instructions. The la-
beled microRNA was controlled using the Enzyme
Linked Oligosorbent Assay (ELOSA) step (Genisphere),
following the manufacturer’s instructions. All samples
showed expected labeling and the resulting targets were
hybridized to miR 2.0 arrays (Affymetrix), containing
15,644 microRNA probe sets from the miRBASE
v15 (http://microrna.sanger.ac.uk). The arrays recognize
microRNA from 131 organisms, including human small
nucleolar RNA such as snoRNA and small Cajal body-
specific RNA (scaRNA) from the Ensembl Archive
(www.ensembl.org/biomart/martview) and snoRNAbase
(http://www-snorna.biotoul.fr/info.php). The arrays were
washed and processed on a Fluidics Station 450 and
scanned with a confocal laser scanner (GeneChip Scan-
ner 3000, Affymetrix) according to the manufacturer's
instructions.
Labeling and hybridization to U133Plus 2.0 DNA
microarrays
As previously described 5.0 ug RNA was reverse tran-
scribed into cDNA (Superscript II, Invitrogen, Carlsbad,
CA) [35]. Biotin-labeled target cRNA was prepared from
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Farmingdale, NY) and hybridized to Human Genome
HG-U133 plus 2.0 arrays (Affymetrix, Santa Clara,
CA), containing 54,675 probe sets, as recommended in
the Affymetrix Gene Chip Expression Analysis manual.
Arrays were scanned with a confocal laser scanner
(GeneChip Scanner 3000, Affymetrix) and visualized using
GCOS. These experiments comply with Minimum In-
formation About a Microarray Experiment (MIAME) [41].
Data analysis of miR_2.0 microarrays
Data from the microarrays were analyzed with Affymetrix
microRNA QC Tool according to the manufacturers’ in-
structions. Robust Multi-array Analysis (RMA) was
used for normalization. To be included in the analysis
the probe sets had to be detected in more than 50% of
the patients and controls. Thereafter, the differential
gene expression was evaluated using Student’s t-test
(two tailed).
Data analysis of DNA microarrays U133Plus 2.0
The DNA and microRNA microarrays (GSE43592) were
processed and normalized together using Probe Loga-
rithmic Intensity Error (PLIER) method [42]. Differences
in gene expression between the groups were investigated
by Student’s t-test (two tailed) using linear models to-
gether with empirical Bayes [43]. P-values from the stu-
dent’s t-test were transformed into Q-values through the
correction for multiple testing [44]. The Q-values were
overlaid on Gene Ontology (GO) networks and then a
reporter algorithm [45,46] was used to evaluate the en-
richment p-value of each GO term. GO terms that had
enrichment P-values < 0.05 were selected in the con-
struction of a heatmap as illustrated in Figure 1. The
analyses were performed using piano package [47] under
the R software environment.
Computational methods to identify microRNA functions
and mRNA targets
The most commonly used microRNA database mirBase
(http://www.mirbase.org) released in November 2011
[6], including over 21643 mature microRNA products
in 168 species, was used to identify microRNA func-
tions and target mRNAs. Multiple computational methods
are developed to predict microRNA target sites [48]
and in general, target prediction algorithms focus on
the complementarities between the microRNA and the
potential targets around the “seed” sequence, hetero-
duplex free energy of binding, location and size of in-
ternal loops and bulges, and accessibility of the target
site as predicted by RNA folding. To predict mRNA
targets to the differentially expressed microRNAs in
the present study, we used TargetScan [49] (http://
www.targetscan.org) and Miranda [50] (http://www.microrna.org/microrna/getDownloads.do). However, there
are some evidence that perfect seed pairing may not
necessarily be a reliable prediction for microRNA-
mRNA interaction since these bioinformatics tools do
not take into account the secondary structure of the
mRNA which may affect the microRNA target recogni-
tion [51]. Therefore, as a way to achieve the high confi-
dence microRNA-mRNA associations and evaluate the
impact of each microRNA on the gene expression, the
predicted microRNA target genes of each microRNA
were identified and combined with mRNA transcriptome
from MS patients and controls. Kolmogorov-Smirnov test
was employed to evaluate the impact of each microRNA
on gene expression between MS patients and controls (the
test was performed over cumulative fraction of gene ex-
pression fold changes of specific microRNA targets and
background, which is the rest of the genes that do not
contain the targets of specific microRNA [5,49]). The re-
sults are reported in Table 1. The identified target genes
were cross referenced against the differentially expressed
mRNAs that differed between MS patients and controls.
Real-time PCR analysis of microRNA expression
Mir-494 and mir-197 were selected for verification and
specific Taqman® MicroRNA assays (Applied Biosystems,
Life Technology, Foster City, CA) were used. Reverse
transcriptase (RT) reactions contained 10 ng RNA, 5 X
stem–loop RT primer, 10× RT buffer, 100 mM dNTPs,
50 U/μl MultiScribe reverse transcriptase and 20 U/μl
RNase inhibitor (Applied Biosystems). The reactions
were incubated for 30 min at 16°C, 30 min at 42°C,
5 min at 85°C. The High Capacity RNA-to-cDNA Kit
(Applied Biosystems) was used for the housekeeping-
gene RPLP0. All reverse transcriptase reactions were
run in duplicate.
Real-time PCR was performed using a standard TaqMan®
PCR kit protocol on an Applied Biosystems 7900HT
Sequence Detection System. The PCR included the RT
product, 1× TaqMan® Universal PCR Master Mix and
TaqMan® Small RNA assay (20 ×). The reactions were
incubated at 95°C for 10 min, followed by 40 cycles of
95°C for 15 s and 60°C for 1 min. The cycle threshold
(Ct) value of the house-keeping gene RPLP0 was
subtracted from the corresponding Ct value for mir-
494 and mir-197 resulting in the ΔCt value and relative
quantification was calculated using the (2-ΔΔCT) for-
mula [52]. Differences were analyzed by Student’s t-test
(two tailed).
Real-time PCR analysis of mRNA expression of TNFSF14
Reagents for real-time PCR analysis of TNFSF14, such as
High Capacity RNA-to-cDNA Kit and TaqMan Universal
PCR Master Mix, were obtained from Applied Biosystems
by Life Technologies (Carlsbad, CA) and used according to
Figure 1 In the DNA microarray analysis we identified 2452 differentially expressed genes (Q < 0.05; PLIER) in peripheral blood T-cells
that differed between MS patients and healthy controls. In order to identify which biological processes the differentially expressed genes
belonged to we used GO. Two hundred and fifty-six genes were classified as immune-related according to GO [53]. The number of genes in each
category is shown in parenthesis. The enrichment score (−log10 (enrichment P-values)) is shown in red for overrepresented gene ontology terms
and in blue for the ones underrepresented in MS patients compared with controls. All gene ontology terms that had P-values < 0.05 are shown.
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to normalize the expression levels between samples. cDNA
was synthesized from 200 ng of total RNA in a reaction vol-
ume of 20 μl. Specific products were amplified and detected
with the ABI Prism 7900HT Sequence Detection System
(Applied Biosystems) using default cycle parameters. All
samples were analysed in triplicates. The relative compara-
tive CT method was used to analyse the real-time PCR data
[52]. Differences were analyzed by Students T-test.Immunoassay analysis of TNFSF14
Serum levels of TNFSF14 were analyzed with a commercial
ELISA from R&D systems (Minneapolis, MN). Intra-assay
coefficient of variation was 5.1% and the limit of detection
was 31 ng/l. Differences were analyzed by Students T-test.
Statistics
The statistics for each analysis is given above in their
subsections. P-values ≤ 0.05 were considered significant
Table 1 Differentially expressed small nucleolar RNA in
T-cells between MS patients and controls
Small nucleolar RNA Fold change MS/Control P-value
mgU12-22-U4-8_s_st 0.66 0.037
mgU2-25-61_s_st 0.84 0.041
SNORD119_st 0.77 0.03
U104_st 0.77 0.027
U105_st 0.83 0.046
U105B_st 0.39 0.023
U17b_st 0.53 0.025
U17b_x_st 0.58 0.02
U27_st 0.57 0.004
U27_x_st 0.55 0.01
U31_st 0.71 0.031
U31_x_st 0.69 0.035
U42B_x_st 0.79 0.042
U56_st 0.43 0.031
U56_x_st 0.33 0.005
U58A_st 0.85 0.02
U59A_st 0.76 0.014
U61_st 0.66 0.01
U79_st 0.81 0.028
U80_st 0.70 0.018
U83_st 0.65 0.02
U83A_x_st 0.80 0.03
U84_x_st 0.75 0.029
v11_hsa-miR-768-3p_st 0.74 0.028
v11_hsa-miR-768-5p_st 0.86 0.025
ACA16_st 0.76 0.014
ACA16_x_st 0.69 0.002
ACA24_x_st 0.68 0.008
ACA44_s_st 0.50 0.048
ACA48_x_st 0.68 0.005
ACA54_st 0.45 0.003
ACA7_s_st 0.40 0.002
ACA7B_s_st 0.52 0.01
E3_x_st 0.73 0.016
ENSG00000201009_s_st 0.58 0.033
ENSG00000206903_s_st 0.54 0.031
ENSG00000206913_s_st 0.40 0.002
ENSG00000212615_x_st 0.77 0.014
ENSG00000239031_st 1.15 0.039
ENSG00000252049_st 1.10 0.046
HBII-210_st 0.42 0.028
HBII-436_st 0.81 0.018
HBII-55_st 0.62 0.04
Table 1 Differentially expressed small nucleolar RNA in
T-cells between MS patients and controls (Continued)
HBII-85-17_x_st 0.85 0.031
HBII-85-29_st 0.65 0.004
HBII-85-3_x_st 0.81 0.003
HBII-85-9_x_st 0.87 0.043
HBII-99_st 0.51 0.011
hp_hsa-let-7d_st 0.90 0.044
hp_hsa-mir-423_s_st 0.52 0.023
Displayed is the fold change in expression between MS patients and controls.
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wise stated.
Results
Differentially expressed microRNA in T-cells between MS
patients and controls
To identify T-cell microRNA with a differential expres-
sion between MS patients and controls we analyzed ap-
proximately 1000 microRNA with microarray analysis.
On the microarrays were also probes for a large
number of small snoRNA and scaRNA. Twenty-one
microRNA had decreased expression in peripheral
blood T-cells in MS patients compared with controls
(Table 2). The mature microRNA sequences are given
in (Additional file 1: Table S2). In addition, 50 small
nucleolar RNA such as snoRNA and scaRNAs were dif-
ferently expressed in T-cells between MS patients and
controls (Table 1).
Differentially expressed mRNA in T-cells between MS
patients and controls
DNA microarray analysis was used to identify differen-
tially expressed T-cell genes between MS patients and
controls. In the DNA microarray analysis we identified
2452 differentially expressed genes (Q < 0.05; PLIER) in
peripheral blood T-cells that differed between MS pa-
tients and healthy controls. In order to identify which
biological processes the differentially expressed genes
belonged to we used GO. Two hundred and fifty-six
genes were classified as immune-related according to
GO [53] and over or under represented biological pro-
cesses for these genes are shown in Figure 1.
Identification of differentially expressed target genes of
microRNA
To better understand the role of the differentially expressed
microRNA in MS patients we first identified the predicted
target genes for each of the microRNA using the databases
TargetScan and Miranda. Second, to investigate if the
significantly changed microRNA had any effect on gene
Table 2 Impact of differentially expressed microRNA on gene expression in T-cells between MS patients and controls
microRNA microRNA microarray Impact of microRNA on its targets (mRNA microarray)
Fold change MS/Control P-value TargetScan Miranda
hsa-miR-494 0.14 3.1 × 10-05 1.2 × 10-24 6.0 × 10-81
hsa-miR-15b 0.14 2.5 × 10-03 4.1 × 10-34 5.5 × 10-15
hsa-miR-30c 0.15 7.7 × 10-04 2.8 × 10-13 5.0 × 10-58
hsa-miR-23a 0.16 7.8 × 10-03 2.2 × 10-23 9.8 × 10-63
hsa-miR-197 0.19 5.2 × 10-06 1.6 × 10-12 1.2 × 10-06
hsa-miR-1260b 0.21 9.4 × 10-07 NA 2.3 × 10-16
hsa-miR-125a-5p 0.22 8.2 × 10-03 1.2 × 10-43 5.3 × 10-13
hsa-miR-361-5p 0.24 1.4 × 10-02 1.8 × 10-15 3.9 × 10-32
hsa-miR-320d 0.26 2.8 × 10-03 2.0 × 10-09 7.4 × 10-36
hsa-miR-423-3p 0.26 1.6 × 10-02 5.0 × 10-13 1.8 × 10-03
hsa-miR-1280 0.29 4.7 × 10-03 8.2 × 10-56 8.6 × 10-04
hsa-miR-663 0.32 3.5 × 10-03 5.9 × 10-70 1.8 × 10-28
hsa-miR-423-5p 0.33 2.6 × 10-02 6.1 × 10-96 5.7 × 10-36
hsa-miR-99b 0.36 2.4 × 10-02 3.4 × 10-04 7.6 × 10-03
hsa-miR-339-5p 0.37 4.9 × 10-02 1.5 × 10-35 2.5 × 10-07
hsa-let-7a 0.37 2.9 × 10-02 1.9 × 10-04 3.2 × 10-09
hsa-miR-1979 0.38 1.2 × 10-02 NA 8.1 × 10-09
hsa-miR-3178 0.39 1.0 × 10-02 NA NS
hsa-miR-625 0.41 3.2 × 10-02 3.6 × 10-62 2.3 × 10-09
hsa-miR-150 0.65 3.7 × 10-02 2.1 × 10-68 2.1 × 10-11
hsa-miR-3153 1.14 4.5 × 10-02 NA 2.4 × 10-09
To investigate the impact of the significantly changed microRNAs on gene expression in T-cells we performed Kolmogorov-Smirnov test using the target genes
identified in TargetScan and Miranda. NS: not significant, NA: not available in the database. Displayed is the fold change in expression between MS patients
and controls.
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the target genes identified in TargetScan and Miranda on
the gene expression data. The results showed that there
were some differences between the two databases
TargetScan and Miranda but that in most cases the same
results were obtained, i.e. that the differently expressed
microRNA did indeed significantly affect the gene expres-
sion (Table 2). Third, to identify which of the differentially
expressed genes that were indeed target genes of the dif-
ferentially expressed microRNA we compared the list of
microRNA target genes with our list of differentially
expressed genes between MS and controls. This resulted
in 920 genes. Fourth, these 920 genes were classified
according GO and 100 genes were classified as being
involved in immune processes. The top 25 genes with
increased and decreased expression between MS and con-
trols, respectively, are shown in Additional file 1: Table S3.
They were further analyzed using functional module en-
richment [54] based on Immune System Gene Ontology
[53] which resulted in 21 modules that were enriched with
separate functions (see following list and Additional file 1:
Figure S1).List of functional module enrichment based on Im-
mune System Gene Ontology on target genes of differ-
entially expressed microRNA between MS patients and
controls:
Antigen processing and presentation of exogenous
peptide antigen via MHC class I, TAP-dependent
T cell migration
Megakaryocyte differentiation
Toll-like receptor 3 signaling pathway
Regulation of response to interferon-gamma
Natural killer cell mediated immunity
Negative regulation of lymphocyte activation
Negative regulation of inflammatory response to
antigenic stimulus
Regulation of inflammatory response to antigenic stimulus
Thymic T cell selection
Natural killer cell differentiation
V(D)J recombination
Megakaryocyte differentiation
Negative regulation of erythrocyte differentiation
Megakaryocyte differentiation
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Dendritic cell chemotaxis
Natural killer cell activation
Regulation of defense response to virus
Positive regulation of monocyte chemotaxis
Regulation of toll-like receptor 3 signaling pathway
The interactions between the 20 microRNA and the
100 genes are shown in Figure 2.Verification of a differently expressed microRNA using
real-time PCR
To verify the results from the DNA microarray analysis
we selected mir-494 and mir-197 because they were
among the microRNAs that had the largest fold change
in expression between MS patients and controls of all
the microRNA (Table 1). We analyzed the expression of
mir-494 and mir-197 with real-time PCR and confirmed
that the expression was significantly decreased in MS
patients compared with controls (P = 0.02 and P = 0.04;
Figure 3A-B).Figure 2 A computational method to identify microRNA function and
microRNA between MS patients and controls, using TargetScan and Mirand
mRNA from peripheral blood T-cells between patients and controls. Square
expression and blue decreased expression between MS patients and contrVerification of TNFSF14 using real-time PCR
To verify the results in the DNA microarray analysis and
predicted mRNA target analysis, we analyzed the expres-
sion of TNFSF14 with real-time PCR and confirmed that
the expression was significantly decreased in MS pa-
tients compared with controls (P = 0.05; Figure 4).
Serum levels of TNFSF14 in MS compared with healthy
controls
To test whether changes in microRNA expression were
accompanied by changes of corresponding proteins we
determined serum levels of TNFSF14 in MS patients
and controls. The serum level of this protein was found
to be significantly decreased in MS patients compared
with controls (P = 0.05; Figure 5).
Discussion
To explore genes and mechanisms involved in MS we
performed global microarray analyses of mRNA and
microRNA in T-cells from MS patients and controls. We
found 2,452 genes and 21 microRNA that differed signifi-
cantly in expression between MS patients and controls. OfmRNA targets in T-cells. Target genes of significantly regulated
a algorithms, were compared with significantly differently expressed
s indicate microRNA and circles mRNA. Red indicates increased
ols.
Figure 3 Verification of the differential expression of A) mir-494 and B) mir-197 between MS patients (n = 16) and healthy controls
(n = 12) by real-time PCR. Data are presented as mean ± SEM.
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of their target genes. When the microRNA target genes
were cross-referenced against the genes that differed in
expression between MS patients and controls 920 genes
were identified and 100 were involved in the immune sys-
tem. To better understand the role of the target genes we
clustered the genes involved in the immune system using
GO. The significantly enriched immune processes ob-
served between MS and controls, points to well known
processes within autoimmunity. Four of the 21 (mir-150,
mir-15b, mir-1979 and mir-23a) identified microRNA in
this study have already been linked to MS, however, not in
CD3+ T-cells [27,28,34,55]. We also found 50 small nucle-
olar RNAs such as snoRNAs and scaRNAs that were dif-
ferently expressed in T-cells between MS patients and
controls. However, in this manuscript we have focused on
microRNA since the amount of information concerningFigure 4 Verification of the differential mRNA expression of
TNFSF14 between the MS patients (n = 13) and healthy controls
(n = 9). Data are presented as mean ± SEM.the smaller molecules such as snoRNA is scarce to say
the least.
We found several genes that were involved in im-
munological pathways previously associated with MS
such as ITGAM, CD8A, CD8B, CCL5, CCR2, TGFBR1
and TNFSF14 among the top genes regulated by the dif-
ferentially expressed microRNA. ITGAM is an integrin
involved in leukocyte migration that is expressed on
T-cells and other leukocytes [56]. ITGAM expression is
critical on T-cells and phagocytes for the development
of EAE in mice [57]. CD8A and CD8B are the two genes
that codes for the subunits of CD8 which is specifically
expressed on cytotoxic T-cells which are involved in
major histocompatibility class I immunosurveillance.
CCL5, also known as RANTES, is a chemokine and T-cells
from MS patients have been shown to have increased mi-
gration towards CCL5 compared with T-cells from healthy
controls [58]. Furthermore, treatment with anti-CCL5
antibodies in EAE mice prevented leukocyte adhesion but
not rolling [59] and a selective antagonist against one of
the receptors for CCL5, namely CCR1, abrogated clinical
disease signs in EAE rats [60]. CCR2 is the receptor forFigure 5 Verification of the protein levels of TNFSF14 between
the MS patients (n = 16) and healthy controls (n = 20). Data are
presented as mean ± SEM.
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(MCP-1). Anti-CCL2 treatment prevented the develop-
ment of paralysis in EAE mice [61] and leukocyte adhesion
[59]. TGFBR1 is the receptor for TGF-β1 and administra-
tion of TGF-β1 protects and even improves the clinical
course of EAE when given during ongoing disease [62].
Furthermore, deletion of TGF-β1 in mice leads to an early
death caused by massive tissue infiltration of lymphocytes
and macrophages resembling autoimmunity [63].
TNFSF14 is a newly identified risk gene for MS along
with its receptor TNFRSF14 (HVEM). A recent study
showed that membrane-bound TNFSF14 is important
for CD4+ memory T-cell survival [64]. Membrane-bound
TNFSF14 is a co-stimulatory molecule [65] which has
diverse stimulatory effects on the immune system.
Over-expression of the membrane-bound form leads on
T-cells leads to autoimmunity in mice [66-68]. It has
also been implicated in asthma and tumor response
[69,70]. In contrast, the soluble form of TNFSF14 has
been shown to act as an inhibitor of activation [71-74].
We chose TNFSF14 for verification by real-time PCR
and ELISA because it had a high expression level and
the fact that there was a soluble form of the protein. In-
deed, we found that both the mRNA and the protein ex-
pression of the microRNA target gene TNFSF14 was
decreased in MS compared with controls.
Limitations of this study include the lack of naïve MS
patients and the lack of gender matching.Conclusion
These findings indicate that microRNA may be import-
ant regulatory molecules in T-cells in MS.Reviewer link to access microarray data
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